The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

A carbohydrate composition includes fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of fucose is 45.5% to 76% by weight; the content of glucuronic acid is 11% to 19% by weight; the content of galactose is 4.5% to 14.5% by weight, and the content of arabinose is 5.5% to 18% by weight. A pharmaceutical ingredient including the above-mentioned carbohydrate composition is provided.

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Provided is a pharmaceutical composition for oral administration in the form of powder obtained by a process including: (a) preparing an emulsion including zanamivir as an active ingredient; triglyceride; acyl glycerol; a nonionic surfactant; a sugar; and water; and (b) lyophilizing the emulsion prepared in the step (a). The pharmaceutical composition according to the presently claimed subject matter can significantly increase in vivo absorption rate of zanamivir. Further, the pharmaceutical composition according to the presently claimed subject matter is in the form of powder, which not only make it easy to store and distribute but also make it possible to avoid the use of functional packaging materials for preventing changes in moisture.

The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed.